Opinion|Videos|November 20, 2026

Outcomes with First-Line Obrixtamig Plus Standard of Care in epNEC by DLL3 Expression Status: Phase Ib DAREON®-7 Study

This Rapid Readout covers results from the DAREON-7 trial, which tested obrixtamig, a T-cell engager that targets DLL3, added to standard platinum-etoposide chemotherapy as first-line treatment for DLL3-positive extrapulmonary neuroendocrine carcinoma.

This Rapid Readout covers results from the DAREON-7 trial, which tested obrixtamig, a T-cell engager that targets DLL3, added to standard platinum-etoposide chemotherapy as first-line treatment for DLL3-positive extrapulmonary neuroendocrine carcinoma. Dr Aman Chauhan of the University of California, San Francisco, reports that the combination’s safety was manageable and in line with each drug given alone, with no severe cytokine release syndrome. He also reports encouraging response rates whatever the level of DLL3 expression, with a trend toward deeper, longer-lasting responses and longer progression-free survival in patients whose tumors express high levels of DLL3. These findings are now being tested in the randomized DAREON-NEC-1 trial.


Related to this article